Last reviewed · How we verify
NCT07008001: CATHAY Ext
Assessment of DOT Spectacles in Chinese Children Extension
NA trial testing Novel spectacle lens design in Juvenile Myopia in 175 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | SightGlass Vision, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 175 |
| Start date | 1 August 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 5 locations across China |
Drugs / interventions tested
- Novel spectacle lens design
Conditions studied
- Juvenile Myopia — all drugs for Juvenile Myopia →
- Myopia — all drugs for Myopia →
Sponsor
SightGlass Vision, Inc.
Who can join
Adults 8 to 16, any sex, with Juvenile Myopia or Myopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07008001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Novel spectacle lens design
Trials testing the same drug.
- NCT07229352 — Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses · NA · not yet recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
- NCT05562622 — Assessment of DOT Spectacles in Chinese Children · NA · active not recruiting
- NCT05650190 — Spectacle Lens Visual Acuity Assessments Study · NA · active not recruiting
- NCT04947735 — CYPRESS Efficacy and Safety Study Extension · NA · active not recruiting
Other recruiting trials for Juvenile Myopia
Currently open trials in the same condition.
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
- NCT06034327 — Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens · NA · recruiting
- NCT05893979 — Myopia Control Spectacle Lens Cessation Study · NA · active not recruiting
- NCT05562622 — Assessment of DOT Spectacles in Chinese Children · NA · active not recruiting
- NCT05617794 — Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness · NA · active not recruiting
Other SightGlass Vision, Inc. trials
Trials by the same sponsor.
- NCT07229352 — Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses · NA · not yet recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
- NCT06034327 — Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens · NA · recruiting
- NCT05893979 — Myopia Control Spectacle Lens Cessation Study · NA · active not recruiting
- NCT05562622 — Assessment of DOT Spectacles in Chinese Children · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07008001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SightGlass Vision, Inc.
- Last refreshed: 29 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07008001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing